Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Biotechnology

Healthcare
$2.75 +1.73%

+$0.14 today

Market cap
$56.57M
Beta
2.59
P/E (TTM)
-1.3
EPS (TTM)
-$6.35
52W Low $6.72High $20.56

Volume 0.63M

Average 0.42M

CRBP Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables growth accelerates

Q1 FY2026 accounts payables of $1.87M (cash outflow) rose 173.1% year over year, ahead of the -272.3% change in trailing-twelve-month accounts payables. Sequentially, it rose 231.2% from the prior quarter. Over 3 fiscal years it compounded at +109.1% a year.

Context

  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +173.1% holds above the trailing-twelve-month pace of -272.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.87M+231.2% QoQ
Last fiscal yearDec 2025
-$2.35M-246.5% YoY
LTMMar 2026
-$3.53M-272.3% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+173.1%——
1 year-246.5%——
3-year CAGR+109.1%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(2.35M) USD
Year-over-year change
-246.5%

Accounts Payables vs competitors

How CRBP compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -272.3% is the lowest of 9, against a peer median of -46.2%.
  • Over three fiscal years its annual growth of +109.1% compares with a peer median of +7.4%.
CRBP Competitors
Accounts Payables for CRBP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBRXForte Biosciences, Inc.LTM Mar 2026$8.06M USD+141.5%+199.2%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$7.58M USD+55.9%—425.1%
CRDFCardiff Oncology, Inc.LTM Mar 2026$5.21M USD+1496.2%+17.8%992.0%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$3.83M USD-230.5%——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$3.53M USD-272.3%+109.1%—
PEPGPepGen Inc.LTM Mar 2026$2.06M USD-230.7%-12.7%—
ALECAlector, Inc.LTM Mar 2026$903K USD-59.8%-2.9%4.9%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$662K USD-192.7%—20.9%
MOLNMolecular Partners AGLTM Mar 2026CHF 504.13K CHF-32.5%——
IPHAInnate Pharma S.A.FY2025€0 EUR——0.0%
Peer median (excluding CRBP) —-46.2%+7.4%20.9%

Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(45.64M)(42.35M)(44.6M)(40.21M)(78.54M)
Depreciation & Amortization1.64M1.49M641K(2.74M)(1.13M)
Deferred Income Tax00000
Stock-Based Compensation9.48M5.72M3.47M6.15M6.29M
Change in Working Capital(15.7M)(4.02M)4.09M(5.58M)9.12M
Accounts Receivables1.62M0000
Inventory00000
Accounts Payables(5.96M)(256.84K)1.03M1.6M(2.35M)
Other Working Capital(11.36M)(3.77M)3.07M(7.18M)11.47M
Other Non-Cash Items2.03M1.62M3.77M585K(229K)
Operating Cash Flow(48.18M)(37.54M)(36.1M)(41.79M)(64.49M)
Capital Expenditures(54.17K)(13.45K)30(7K)
Acquisitions (Net)08.1K000
Purchases of Investments(87.27M)(86.34M)(33.88M)(180.8M)(163.09M)
Sales of Investments13.88M116.42M69.53M59.49M161.46M
Other Investing Activities23.9K0000
Investing Cash Flow(73.42M)30.07M35.64M(121.31M)(1.64M)
Debt Repayment57.78K(533.62K)(2.87M)(15.48M)0
Common Stock Issued62.59M053.4K182.06M77.43M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.82M)0000
Financing Cash Flow60.82M(533.62K)(2.82M)166.58M77.43M
Effect of Forex Changes00000
Net Change in Cash(60.78M)(8M)(3.28M)3.47M11.29M
Free Cash Flow(48.24M)(37.56M)(36.1M)(41.79M)(64.5M)

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Intrinsic Alpha fair value

Locked

Current Price

$2.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.